CCL2 facilitates spinal synaptic transmission and pain via interaction with presynaptic CCR2 in spinal nociceptor terminals

Sui-Bin Ma1†, Hang Xian1,2†, Wen-Bin Wu3†, Shuo-Yao Ma4, Yu-Ke Liu5, Yu-Tong Liang5, Huan Guo1,6, Jun-Jun Kang1, Ying-Ying Liu1, Hui Zhang1,7, Sheng-Xi Wu1, Ceng Luo1* and Rou-Gang Xie1*

Abstract

Previous studies have shown that CCL2 may cause chronic pain, but the exact mechanism of central sensitization is unclear. In this article, we further explore the presynaptic role of CCL2. Behavioral experiments show that intrathecal foramen injection CCR2 antagonists into dorsal root ganglion (DRG) can inhibit the inflammatory pain caused by CCL2 in spinal cord. We raised the question of the role of presynaptic CCR2 in the spinal dorsal horn. Subsequent electron microscopy experiments showed that CCR2 was expressed in the presynaptic CGRP terminal in the spinal dorsal horn. CCL2 can enhance presynaptic calcium signal. Whole-cell patch-clamp recordings showed that CCL2 can enhance NMDAR-eEPSCs through presynaptic effects, and further application of glutamate sensor method proved that CCL2 can act on presynaptic CCR2 to increase the release of presynaptic glutamate. In conclusion, we suggest that CCL2 can directly act on the CCR2 on presynaptic terminals of sensory neurons in the spinal dorsal horn, leading to an increase in the release of presynaptic glutamate and participate in the formation of central sensitization.

Keywords: Chemokines C, C motif chemokine ligand 2 (CCL2), C motif receptor 2 (CCR2), Spinal synaptic transmission, Nociceptor, Pain

Introduction

There is growing evidence that neuroinflammation plays a key role in the pathogenesis of neuropathic and inflammatory pain. [1, 2]. Most known inflammatory mediators cause pain by binding to nociceptors, located in the peripheral nervous system [3–5]. Previous studies have demonstrated that chemokines are associated with chronic pain after nerve injury [6, 7] and chronic itch [8, 9]. Chemokines C–C motif chemokine ligand 2 (CCL2), also known as monocyte chemotactic protein 1 (MCP-1), which can recruit monocytes to reach inflammation, infection, trauma, ischemia and other sites.

Chemokines C–C motif receptor 2 (CCR2) is the main receptor of CCL2. Evidence suggests that CCL2/CCR2 is involved in neuropathic pain [10, 11]. Zhang and De Koninck [12] found that CCL2 expression was increased in small- to large-diameter DRG neurons after ganglion ligation, which expressed nerve damage marker ATF-3. This result indicates that CCL2 expression was increased in injured neurons. Thacker et al. [13] found that after ligation of L5 nerve root, CCL2 can be produced in both the injured L5 and the undamaged L4 peripheral sensory neurons. Intrathecal injection of CCL2 causes inflammatory hyperalgesia [14]. DRG neurons can transport the generated CCL2 to the central terminal of the spinal cord through axoplasmic transport. CCL2 was found to be expressed in SP and CGRP-positive primary afferent fibers in the superficial dorsal horn of spinal cord [11, 15]. Nerve injury can induce CCL2 axoplasmic transport.
to the central terminal [13]. It is worth noting that the release of CCL2 in the spinal terminals of primary afferent neurons is activity-dependent. Strong electrical stimulation of dorsal root can quickly release CCL2 in the superficial layer of nerve-injured spinal dorsal horn [13]. However, the synaptic mechanism of CCL2-induced pain sensitization is not entirely clear.

Our previous study has shown that CCL2 can directly regulate the synaptic plasticity of excitatory neurons expressing CCR2 in the spinal cord lamina IIo, which is the basis for central sensitization in chronic pain [14]. We further demonstrate that CCL2 can directly interact with CCR2 to enhance NMDAR-induced currents, eventually leading to inflammatory pain mainly through CCL2-CCR2-pERK-GluN2B pathway [16]. However, there are still some issues that need to be further clarified. For instance, whether the presynaptic terminals express CCR2? What is the role of CCR2 in synaptic terminals? Utilizing patch clamp recordings together with biochemical as well as behavioral surveys, we demonstrated that CCL2 can directly act on the CCR2 located in presynaptic terminals of sensory neurons in the spinal dorsal horn, and leading to an increase in the release of presynaptic glutamate and participate in the formation of central sensitization.

Methods
Animals and pain model
C57Bl/6 background WT mice were purchased and bred in the Animal Facility of the Fourth Military Medical University. Young mice (4–6 weeks old, C57Bl/6) were used for electrophysiological studies in spinal cord slices. All the animal procedures were approved by the Animal Care Committee of the Fourth Military Medical university.

Intrathecal administration
C57Bl/6 mice were anaesthetized with 1% pentobarbital sodium. A midline incision was made along L2 to L4 vertebral plate and the muscle attached to spinous process removed [17]. With the tip of the sharp scissor, a 1-mm hole on the left vertebra was made until dura and clean CSF was exposed. An intrathecal catheter (polyethylene-10 tubing) was inserted from L3 and passed rostrally into the subarachnoid space until it reached L1/T13. After a flush with 10 μl saline, the exterior end of catheter was sealed by heat. Penicillin antibiotics were used to prevent infection at the end of intrathecal catheterization. The mice were allowed to recover for 3 days. Any mouse showing motor deficits would be excluded. CCL2 (5 μl) diluted by normal saline was intrathecally applied 3 day after intrathecal catheter implantation.

DRG injection of RS504393
C57Bl/6 mice were anaesthetized with 2% isoflurane. The procedure for intervertebral foramen injection of RS504393 was the same as described previously [18, 19]. In brief, the bilateral iliac spines were exposed to locate the L3 and L4 vertebrae of mice. The 26-gauge needle mated to a Hamilton syringe (Hamilton, Reno, NV) was inserted at a 45° angle at the intersection of the lower edge of the ipsilateral L3 and L4 vertebrae. There was a sense of restriction when the needle entered the transverse foramen, and the paw retraction reaction of mice was the sign of the needle entering the transverse foramen. The L3/L4 intervertebral foramen was hence infiltrated with RS504393 (1 μg/20 μg) or vehicle. RS504393 was suspended in a 1% DMSO/saline mix.

Behavioral analysis
Animals were habituated in the testing environment for at least 2 d before baseline testing. Thermal hyperalgesia and mechanical allodynia were tested as previously described [14, 20]. The experimenters were blinded to treatments.

Spinal cord slice preparation and patch-clamp recordings
As we previously reported [14], the Krebs’ solution contains (in mM): 127 NaCl, 3.6 KCl, 2.4 CaCl2, 1.3 MgCl2, 1.2 NaH2PO4, 26 NaHCO3, and 15 glucose. After establishing the whole-cell configuration, neurons were held at the potential of + 40 mV to record NMDAR evoked EPSCs (NMDAR-eEPSCs) by stimulating the dorsal root entry zone via a concentric bipolar electrode using an isolated current stimulator [20]. The internal solution contains (in mM): 110 Cs2SO4, 2 KCl, 0.1 CaCl2, 2 MgCl2, 1.1 EGTA, 10 HEPES, 5 ATP-Mg. QX-314 (5 mmol/L) was added to the pipette solution to prevent discharge of action potentials. Signals were filtered at 2 kHz and digitized at 5 kHz. Data were stored and analyzed with a personal computer using pCLAMP10 software (Molecular Devices).

Immunofluorescence labelling
Immunohistochemistry was performed according to standard protocols, and the following primary antibodies were used: Isolectin B4 antibody (Biotinylated GRIFFONIA, 1:200, vector laboratories, B-1205), CGRP antibody (Goat, 1:300, Abcam, ab36001), NF200 antibody (mouse, 1:200, Sigma-Aldrich, N5389), CCR2 antibody (rabbit, 1:300, NOVOUS, NB51-48,337), Alexa Fluor® 594 (donkey anti-rabbit IgG, 1:1000, Abcam, ab150132), Alexa Fluor® 488 (donkey anti-mouse IgG, 1:1000, Abcam, ab150105; donkey anti-goat
Images were acquired at 1 Hz. Fluorescence intensity of pus FV1200 confocal microscope (Olympus, Japan). was visualized using an upright super-resolution Olympus of nociceptors in the superficial spinal dorsal horn were obtained. iGluSnFR signal in the presynaptic terminals was measured. Bath application of CCL2 (100 ng/mL) was used to activate the fluorescence signal intensity in the presynaptic terminals of nociceptors.

Pre-embedding immunogold-silver cytochemistry

The protocol was adapted from the previous investigation [22]. Briefly, mice were deeply anesthetized and transcardially perfused with PBS followed by 4% paraformaldehyde and 0.05% glutaraldehyde in 0.1 M PB. The spinal cords were removed and postfixed in the same fixative for 4 h at 4 °C. Serial coronal sections at 100 μm thicknesses (VS1000s, Leica, Heidelberger, Germany). The 0.05% Triton X-100 was used for CCR2 immunogold-silver cytochemistry. After rinsing, the sections were postfixed in 2% glutaraldehyde in PBS for 45 min. Signals of CCR2 immunoreactivity were detected by silver enhancement kit in the dark (HQ Silver Kit, Nanoprobes). Sections were postfixed in 0.5% osmium tetroxide in 0.1 M PB for 2 h. They were dehydrated with graded ethanol, replaced with propylene oxide, and finally embedded in Epon 812 between plastic sheets. Flat-embedded sections were examined under the light microscope. The sections containing CCR2 immunoreactivity in spinal dorsal horn were cut with a diamond knife (Diatome, Hatfield, PA). After counterstaining with uranyl acetate, ultrathin sections were examined under the JEM-1230 electron microscope (JEOL LTD, Tokyo, Japan). Postsynaptic and presynaptic membrane, synaptic vesicles were measured using ImageJ (NIH) by observers blinded to the genotype of the samples.

Statistical analysis

Differences between groups were compared using 1-way ANOVA or 2-way repeated measures ANOVA followed by Bonferroni’s test or by Student’s t test (2-tailed) if only 2 groups were applied. The criterion for statistical significance was \( P < 0.05 \).

Results

Ganglionic injection of RS504393 inhibits the mechanical and thermal hyperalgesia caused by intrathecal CCL2

Consistent with our previous study [14, 16], intrathecal CCL2 (100 ng) induced rapid mechanical hyperalgesia and thermal hyperalgesia, as characterized by a prominent drop in mechanical threshold and latency of paw withdrawal (Fig. 1 A&B, \( n = 10, P<0.001 \)). To further investigate the presynaptic mechanism of spinal cord central sensitization induced by CCL2, we apply DRG administration method to intervertebral foramen injection CCR2 blocker RS504393 (1 μg, 20 μg) into L3/L4 of DRG. Interestingly, ganglionic injection of CCR2 blocker RS504393 dose-dependently attenuated mechanical hyperalgesia and thermal hyperalgesia caused by
intrathecal CCL2 (100 ng), respectively (Fig. 1a, b, n = 10, P < 0.05). In contrast, ganglionic delivery of RS504393 did not alter the basal mechanical threshold and thermal latency (Fig. 1c, d, n = 10, P > 0.05).

**CCR2 is widely expressed in DRG displays upregulation upon peripheral inflammation**

In order to further verify that CCL2 can act on the pre-synaptic terminals in the superficial spinal dorsal horn, we employed immunohistochemical fluorescence methods to verify the expression of CCR2 in DRG. An anti-CCR2 antibody showed the wide immunoreactivity in DRG neurons of naïve mice. Confocal analysis revealed a colocalization of CCR2 in isolectin B4 (IB4)-labeled non-peptidergic nociceptors, CGRP-expressing peptidergic nociceptors as well as NF200-immunoreactive large-diameter sensory neurons (Fig. 2a, c, e). The co-staining rates of CCR2 with IB4, CGRP and NF200 are

**Fig. 1** Ganglionic injection of RS504393 inhibits the mechanical and thermal hyperalgesia caused by intrathecal CCL2. a Prevention of CCL2 (100 ng, i.t.)-induced mechanical hyperalgesia by RS504393 (1 μg, 20 μg, intervertebral foramen injection (i.f.)). b Reversal of CCL2-induced heat hyperalgesia by RS504393 (1 μg, 20 μg, i.f.). c, d Basal mechanical threshold (c) and thermal latency (d) was not altered by RS504393 (20–80 μg, i.f.). *and#and## P < 0.05, **and## P < 0.01, ***and### P < 0.001. Two-Way ANOVA followed by post-hoc Bonferroni test (n = 10–11 mice/group). Data are expressed as mean ± SEM

---

**Fig. 2** a, c, e Immunohistochemical analysis of CCR2 expression in DRG. a, c, e Confocal analysis revealed a colocalization of CCR2 in isolectin B4 (IB4)-labeled non-peptidergic nociceptors (IB4, green), CGRP-expressing peptidergic nociceptors (CGRP, red) and NF200-immunoreactive large-diameter sensory neurons (NF200, blue). The co-staining rates of CCR2 with IB4, CGRP and NF200 are...
Ma et al. Mol. Brain (2020) 13:161

Page 5 of 13

Fig. 2 CCR2 is widely expressed in DRG neurons and displays upregulation following peripheral inflammation. **a, b** Typical examples and quantitative summary from dual immunofluorescence experiments showing CCR2 immunoreactivity IB4-binding non-peptidergic DRG neurons in the naïve and CFA-inflamed mice. **c, d** Immunofluorescence experiments and quantitative summary showing the coexistence of CCR2 immunoreactivity in CGRP-expressing peptidergic DRG neurons in naïve mice and its upregulation in CFA-inflamed mice. **e, f** Immunofluorescence staining and quantitative summary showing the colocalization of CCR2 immunoreactivity with NF200-positive large-diameter DRG neurons in naïve mice and no significant change in expression level after CFA inflammation. Note that in CFA-inflamed group, ipsilateral L3/L4 DRGs were obtained and analyzed at 24 h after intraplantar CFA injection. Arrows indicate the co-expressing cells. **P < 0.01. Two-Way ANOVA followed by post-hoc Bonferroni test (n = 4 mice/group). Data are expressed as mean ± SEM.

14.7%, 33.3% and 44%, respectively in naïve state (Fig. 2b, d, f, n = 12 slices from 4 mice). Following peripheral inflammation induced by intraplantar CFA injection, the proportion of neurons co-labeled with CCR2 and CGRP was dramatically increased (Fig. 2c, d, 59.3% after CFA versus 33.3% control, n = 12, P < 0.01), while that of
neurons co-labeled with CCR2 and IB4 or NF200 was not altered (Fig. 2a, b, e, f, \( P > 0.05, n = 12 \) slices from 4 mice).

**CCR2 is co-labeled with CGRP and IB4 in the superficial layer of spinal cord**

In order to further verify that CCL2 can act on the CCR2 receptor of the presynaptic terminal in the superficial spinal dorsal horn, we used the immunohistochemical fluorescence method to further verify the co-staining of the central terminal of DRG and CCR2. Our results showed that in the superficial layer of spinal cord of naïve mice, CCR2 is sparsely expressed in IB4-labeled non-peptidergic nociceptive terminals (4.1% of co-staining rate), but strongly with CGRP-expressing peptidergic nociceptive terminals (10.94% of co-staining rate) (Fig. 3a–d). Upon hindpaw CFA inflammation, CCR2 expression in superficial spinal dorsal horn displayed significant upregulation (Fig. 3a, c). CCR2 starts to be expressed in IB4-labeled terminals in superficial spinal dorsal horn of CFA-inflamed mice (Fig. 3a, b, n = 12 slices from 4 mice, \( P < 0.01 \)). It is noteworthy that CCR2 is profoundly upregulated CGRP-expressing nociceptive terminals after CFA inflammation (Fig. 3c, d, n = 12 slices from 4 mice, \( P < 0.001 \)). These results suggest that CCL2 may act on CCR2 expressed in the central process terminals of sensory neurons.

**Ultrastructural localization of CCR2 in the presynaptic terminals of spinal dorsal horn**

In order to prove that CCR2 exists in the central process of sensory neurons in the superficial spinal dorsal horn, we further applied the method of immunoelectron microscopy to label CCR2 with fluorescent gold in the spinal dorsal horn. The results showed that CCR2 not only exists in large numbers of postsynaptic neurons and glial cells in the superficial layer of the spinal dorsal horn, but also expressed on the presynaptic nerve.

---

**Fig. 3** CCR2 is co-labeled with CGRP-expressing and IB4-binding terminals in superficial spinal dorsal horn and displays upregulation upon inflammation. **a, b** Immunofluorescence staining and quantitative summary showing an increase in CCR2-immunoreactivity in IB4-positive terminals in the ipsilateral (injured) dorsal horn at 24 h after CFA. **c, d** CCR2-immunoreactivity in CGRP-positive terminals are strongly increased in the ipsilateral (injured) dorsal horn at 24 h after CFA. Arrows indicate the co-expressing terminals. **\( * * P < 0.01, \* * * P < 0.001 \) Two-Way ANOVA followed by post-hoc Bonferroni test (n = 4 mice/group). Data are expressed as mean ± SEM.
terminals in the superficial layer of the spinal dorsal horn (Fig. 4a–f  n = 4). At the same time, electron microscopy results showed that fluorescent gold-labeled CCR2 was expressed in presynaptic nerve endings with huge dense vesicles (Fig. 4a, e). Studies have shown that this kind of nerve endings are presynaptic nerve endings that express CGRP [23]. The above results further prove that CCR2 is expressed in CGRP-positive presynaptic nerve endings in the superficial spinal dorsal horn.

**CCL2 promotes presynaptic calcium signal enhancement via interaction with CCR2**

So, what function does CCR2 expressed in the superficial layer of the spinal dorsal horn have? It is assumed that abnormal increase of intracellular Ca\(^{2+}\) plays crucial roles in the development of chronic pain [24, 25]. We sought to ask whether CCR2 is involved in the mobilization of Ca\(^{2+}\) in DRG neurons and its presynaptic spinal terminals. To address this, we applied genetic technology and microinjection methods to inject the rAAV-EF1a-DIO-GCaMP6s-WPRE-hGH-pA virus into L3/L4 DRGs of SNS-Cre mice. 4 weeks later, we obtained the entire DRG and cut the spinal cord section attached with dorsal root at 350–400 μm-thickness. Confocal microscopy was used to observe the calcium signal changes in the DRG neurons and its presynaptic nociceptive terminals in superficial spinal dorsal horn (Fig. 5a, b). Our results showed that bath application of CCL2 can directly induce the calcium signals in the DRG (Fig. 5c, h, n = 14, \(P < 0.05\)) and the superficial presynaptic terminals of the spinal dorsal horn (Fig. 5d, i, n = 11, \(P < 0.05\)), as characterized by elevation of GCaMP6s fluorescence. This result suggests that CCL2-CCR2 can actively mobilize intracellular Ca\(^{2+}\) in nociceptive primary sensory neurons and presynaptic terminals.

Next, we went on to assess whether CCL2-CCR2 modulates the increase of Ca\(^{2+}\) induced by repetitive activation of nociceptors. Previous studies have shown
that conditioning long frequency stimulation of dorsal root at C-fiber intensity produces synaptic LTP in spinal-PAG (periaqueductal gray) projection neurons, which is assumed to be a cellular basis for pain hyper-sensitivity [21, 26, 27]. As shown in Fig. 5e, conditioning stimulation of dorsal root (2 Hz, 3 mA, 2 min) elicited a prolonged Ca^{2+} enhancement in presynaptic nociceptive terminals, which was almost abolished by co-application of CCR2 inhibitor, RS504393 (50 nmol/L) (Fig. 5f, j, n = 10–13, P < 0.05). In contrast, cotreatment with CCL2 strongly facilitated the Ca^{2+} elevation induced by conditioning stimulation (Fig. 5g, j, n = 10–13, P < 0.05). Taken together, we can infer from the above that CCL2 promotes presynaptic Ca^{2+} signals via interaction with CCR2 localized in presynaptic spinal terminals of nociceptors.

CCL2 facilitates presynaptic glutamate release by acting on presynaptic CCR2
Since transmitter release is known to be Ca^{2+} dependent, CCL2-induced Ca^{2+} influx and Ca^{2+} enhancement may lead to increased transmitter release and synaptic potentiation. To address this possibility, we further applied genetic methods to inject rAAV-EF1a-DIOiGluSnFR(A184S)-WPRE-hGH-pA virus into L3/L4 DRGs of SNS-Cre mice for monitoring presynaptic glutamate release from nociceptive primary sensory neurons (Fig. 6a). As shown in Fig. 6b, bath application of CCL2 (100 ng/mL) elicited dramatic release of glutamate from presynaptic terminals, manifesting as a gradual increase of fluorescence (Fig. 6b–d, n = 18–22, P = 0.0077). Pretreatment with CCR2 inhibitor, RS504393 (50 nmol/L) produced a marked blockade of fluorescence enhance-

ment, indicating that CCL2 facilitates presynaptic glutamate release via interaction with CCR2 (Fig. 6b, c, e n = 18–22, P = 0.0015).

Our previous studies have shown that CCL2 acts on the excitatory neurons of Lamina II in the dorsal horn of spinal cord, and produces hyperalgesia by enhancing the NMDA currents of Vglut2^{+} and SOM^{+} neurons [14]. In this process, does CCL2 act on pre-synapses and play a role? We used the whole-cell patch clamp experiment to detect the response of spinal cord Lamina II neurons to CCL2. We also performed the paired-pulse ratio (PPR) analysis, which represents a short-term plasticity and is well accepted as an indication of presynaptic mechanisms of long-term potentiation in the hippocampus [28]. Consistent with our previous report [14], bath application of CCL2 significantly increased the amplitude of NMDAR-mediated eEPSCs (Fig. 6f and g, n = 7, P = 0.0183). In addition to the postsynaptic mechanisms involved in this process [14], we are interested to know whether presynaptic mechanisms of CCL2 are involved as well. To this end, we plotted the paired-pulse ratio (PPR) of the entire cohort of recorded neurons before and after application of CCL2 (Fig. 6h). The spots falling in the diagonal line represent no significant change of PPR, the vertical distance of each spot to the diagonal line is manifested as the magnitude of change of PPR. Quantification analysis revealed that application of CCL2 showed much stronger changes of PPR, as compared to application of vehicle (Fig. 6i, n = 7, P = 0.0091). The above results suggest that CCL2 may act on presynaptic CCR2 and lead to an increased probability of glutamate release, which in turn results in synaptic potentiation and ultimately pain hypersensitivity.

Discussion
Our study found that intervertebral foramen injection CCR2 antagonists into DRG can inhibit the inflammatory pain caused by CCL2. Subsequent electron microscopy experiments showed that CCR2 was expressed in the presynaptic CGRP terminal in the dorsal horn of the spinal cord. Furthermore, CCL2 can directly induce the calcium signals in the DRG and the superficial presynaptic terminal of the spinal dorsal horn, CCL2 can also enhance presynaptic calcium signal by 2 Hz stimulation. Whole-cell patch-clamp recordings showed that CCL2 can enhance NMDAR-eEPSCs through presynaptic effects, and further application of glutamate sensor method proved that CCL2 can act on presynaptic CCR2 to increase the release of presynaptic glutamate. In conclusion, we prove that CCL2 can directly act on the CCR2 on presynaptic terminals of sensory neurons in the dorsal horn of the
spinal cord, lead to an increase in the release of presynaptic glutamate and participate in the formation of central sensitization.

Although CCL2 can recognize a variety of chemokine receptors, including CCR1, CCR2 and CCR4 [2, 29, 30], CCR2 is its main receptor [30, 31]. Similarly, CCR2 can also bind a variety of chemokines, including CCL2, CCL7 and so on. In mice tissues, the ability of CCR2 to bind to CCL2 is ten times that of CCL7 [30]. Tanaka et al. [32] reported that after partial sciatic nerve ligation (PNSL), CCL2 on DRG neurons was rapidly upregulated (less than 4 h). In situ hybridization experiments showed that CCR2 mRNA was up-regulated in the compressed segment (L4/L5) and the adjacent non-compressed segment (L3/L6) after chronic compression of DRG [33]. CCR2 is up-regulated in the DRG expression of sciatic nerve demyelination model [31, 33, 34]. It fully shows that the up-regulation of CCR2 on DRG is an important factor in inducing pain. However, it is not clear whether the upregulation of CCR2 on DRG cells can be transmitted to the spinal cord and play a role in the process of central sensitization. Our study further proves that CCR2 is highly expressed in the sensory neurons of the dorsal horn of the spinal cord after inflammatory injury, which may be an important reason for central sensitization caused by inflammation.

On isolated spinal cord slices, the application of CCL2 can rapidly increase the frequency of sEPSCs in spinal dorsal horn lamina II neurons [11], suggesting that CCL2 may enhance the release of glutamate through the presynaptic mechanism [8, 35, 36]. However, the reason why CCL2 causes the release of presynaptic glutamate is not clear. We have used electron microscopy, virology, glutamate sensor and other methods to further verify that CCL2 can act on the presynaptic CCR2 receptor, thereby enhancing the release of presynaptic glutamate.

It has become clear that neuroinflammation, mainly mediated by pro-inflammatory cytokines and chemokines, plays an important role in the establishment and maintenance of neuropathic pain. Previous studies have found that the chemokine CX3CL1 is expressed in primary afferent nerves and spinal cord neurons, and induces microglia activation through its microglia receptor CX3CR1 (neuron to microglia signaling) [37]. CCL2 are expressed in spinal cord astrocytes and act on CCR2 in spinal cord neurons to increase excitatory synaptic transmission (astrocytes to neurons signaling) [37]. Our research further found that CCR2 is expressed in the primary afferent nerve terminal, suggesting that the signal transduction of astrocytes to neurons also directly promotes the synaptic release of the primary afferent terminal of the spinal dorsal horn. There is also possibility that the effects were induced by interaction of CCL2 and CCR2 in postsynaptic neurons or glia cells indirectly.

Although studies have shown that CCL2 is highly expressed in IB4-positive nerve terminals in zymosan-induced hyperalgesia [38], studies have also shown CCL2 is mainly expressed on IB4-positive and CGRP-positive neurons in DRG [39]. Our research further confirmed that CCR2 is mainly expressed in CQR-positive DRG neurons and nerve terminals, and CCR2 expression is upregulated after inflammatory pain model which further clarify the presynaptic target of CCL2 in the spinal cord. At the same time, we further explained the potential presynaptic analgesic mechanism of CCR2 as an analgesic target. A large number of studies have shown that DRG neurons are divided into different types according to their markers and excitability [40, 41]. Therefore, in which neuron subtype CCL2/CCR2 functions is worthy of further investigation.

Studies have shown that changes in presynaptic structure and function will lead to changes in synaptic plasticity in spinal cord [21]. Will the upregulation of presynaptic CCR2 cause changes in the synaptic plasticity of the spinal dorsal horn? This may be a potential mechanism of central sensitization.

CCR2 is also expressed in the pre-synapses of the superficial dorsal horn of the spinal cord. At the same time, under noxious injury conditions, the pre-synapses will also release CCL2. Meanwhile, the CCL2 released at the presynaptic terminal can directly act on the presynaptic CCR2, resulting in an increase in the probability of glutamate release, leading to central sensitization.
In summary, our present results demonstrate that CCR2 expressed in presynaptic nociceptor terminals is a key determinant for the initiation of central sensitization and further pain hypersensitivity associated with peripheral inflammation. Further mechanistic analysis reveals that injury or inflammation-induced production of CCL2 may directly interact with CCR2 in presynaptic nociceptor terminals, leading to increase of presynaptic glutamate release and participate in the formation of central sensitization, which in turn results in the exaggerated pain response. This study presents a strong basis for opening up a novel therapeutic target, CCR2 in nociceptors for treatment of pain hypersensitivity.

Abbreviations
CCL2: Chemokines C–C motif chemokine ligand 2; CCR2: Chemokines C–C motif receptor 2; DRG: Dorsal root ganglion; eEPSCs: Evoked excitatory postsynaptic currents; MCP‑1: Monocyte chemotactic protein 1; IB4: Isoclectin B4; CFA: Complete Freund’s adjuvant; PAG: Periaqueductal gray; PPR: Paired-pulse ratio; NMDAR: NMDA receptor.

Acknowledgements
Not applicable.

Authors’ contributions
RGX and CL designed the study. SBM, HX, WBW, SYL, YTL, HG, JJK, YYL, HZ, SXW. Performed experiments and analyzed data. RGX and CL supervised the project and experiments. RGX and CL wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81870867) and Shaanxi Natural Science Foundation of China (No. 81502102).

Availability of data and materials
The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request.

Ethics approval and consent to participate
This study was performed according to the Helsinki Declaration and approved by the ethical committee of the Fourth Military Medical University. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Neurobiology, Fourth Military Medical University, Xi’an 710032, China. 2 Department of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China. 3 The Fourth Regiment, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China. 4 The Sixth Regiment, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China. 5 Pain and Related Diseases Research Laboratory, Medical College of Shantou University, Shantou 515041, China. 6 Department of Health Statistics, Fourth Military Medical University, Xi’an 710032, China.

References
1. Kiguchi N, Kobayashi Y, Kishikoa S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012;12(1):55–61.
2. White PA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA. 2007;104(11):20151–8.
3. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–84.
4. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014;13(7):533–48.
5. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16(11):1248–57.
6. Abbade C, Bangoo S, De Koninck Y, Malcangio M, Mellik-Parsandani‑antz S, White PA. Chemokines and pain mechanisms. Brain Res Rev. 2009;60(1):125–34.
7. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56–68.
8. Jing PB, Cao DL, Li SS, Zhu M, Bai XQ, Xue XB, et al. Chemokine receptor CXCR3 in the spinal cord contributes to chronic itch in mice. Neurosci Bull. 2018;34(1):54–63.
9. Jiang H, Cui H, Wang T, Shimada SG, Sun R, Tan Z, et al. CCL2/CCR2 signaling elicits itch- and pain-like behavior in a murine model of allergic contact dermatitis. Brain Behav Immun. 2019;80:464–73.
10. Liu XJ, Liu T, Chen G, Wang B, Yu XL, Yin C, et al. TLR signaling adaptor protein MyD88 in primary sensory neurons contributes to persistent inflammatory and neuropathic pain and neuroinflammation. Sci Rep. 2016;6:28188.
11. Gao YJ, Zhang L, Samad OA, Suter MR, Yasukihoko K, Xu ZZ, et al. JNK‑induced MCP‑1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci. 2009;29(13):4096–108.
12. Zhang J, De Koninck Y. Spatial and temporal relationship between monocyte chemoattractant protein‑1 expression and spinal glial activation following peripheral nerve injury. J Neurochem. 2006;97(3):772–83.
13. Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13(3):263–72.
14. Xie RG, Gao YJ, Park CK, Lu N, Luo C, Wang WT, et al. Spinal CCL2 promotes central sensitization, long‑term potentiation, and inflammatory pain via CCR2: further insights into molecular, synaptic, and cellular mechanisms. Neurosci Bull. 2018;34(1):13–21.
15. Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P, Mauborgne A, et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist‑treated rats. J Neurochem. 2008;106(2):757–69.
16. Zhang H, Ma SB, Gao YJ, Xing JL, Xian H, Li ZZ, et al. Spinal CCL2 promotes pain sensitization by rapid enhancement of NMDA‑induced currents through the ERK‑GluN2B pathway in mouse lamina II neurons. Neurosci Bull. 2020. https://doi.org/10.1007/s12264‑020‑00557‑9.
17. Liu DL, Lu N, Han WJ, Chen RG, Cong R, Xie RG, et al. Upregulation of Ih expressed in IB4-negative Adelta nociceptive DRG neurons contributes to mechanical hypersensitivity associated with cervical radiculopathy. Sci Rep. 2015;5:16713.
18. Wang F, Ma SB, Tian ZC, Cui YT, Cong XY, Wu WB, et al. Nociceptor‑localized cGMP‑dependent protein kinase I is a critical generator for central sensitization and neuropathic pain. Pain. 2020. https://doi.org/10.1097/j.pain.0000000000002013.
19. Luo WJ, Yang F, Yang F, Sun W, Zheng W, Wang XL, et al. Intervertebral foramen injection of ozone relieves mechanical allodynia and enhances analgesic effect of gabapentin in animal model of neuropathic pain. Pain Physician. 2017;20(5):E673–85.
20. Chen G, Xie RG, Gao YJ, Xu ZZ, Zhao LX, Bang S, et al. Beta-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. Nat Commun. 2016;7:12531.
21. Luo C, Gangadharan V, Bai KK, Xie RG, Agarwal N, Kurejova M, et al. Presynaptically localized cyclic GMP‑dependent protein kinase I is a key
determinant of spinal synaptic potentiation and pain hypersensitivity. PLoS Biol. 2012;10(3):363–94.

22. Kang JJ, Guo B, Liang WH, Lam CS, Wu SX, Huang XF, et al. Daily acute intermittent hypoxia induced dynamic changes in dendritic mitochondrial ultrastructure and cytochrome oxidase activity in the pre-Botzinger complex of rats. Exp Neurol. 2019;313:124–34.

23. Nasu F. Analysis of calcitonin gene-related peptide (CGRP)-containing nerve fibres in the rat spinal cord using light and electron microscopy. J Electron Microsc. 1999;48(3):267–75.

24. Luo C, Sperling R, Kuner R. Activity-dependent potentiation of calcium signals in spinal sensory networks in inflammatory pain states. Pain. 2008;140(2):358–67.

25. Kuner R. Central mechanisms of pathological pain. Nat Med. 2010;16(1):125–86.

26. Ikeda H, Stark J, Fischer H, Wagner M, Dridi R, Jager T, et al. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science. 2006;315(580):1659–62.

27. Sandkühler J. Translating synaptic plasticity into sensation. Brain. 2015;138(Pr 9):2463–4.

28. Schulz PE, Cook EP, Johnston D. Using paired-pulse facilitation to probe the mechanisms for long-term potentiation (LTP). J Physiol Paris. 1995;89(1):3.

29. Savarin-Vuillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics. 2007;4(4):590–601.

30. Kunura T, Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem. 1996;271(20):11603–7.

31. Jung H, Bhangoo S, Banisadr G, Freitag C, Ren D, White FA, et al. Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J Neurosci. 2009;29(25):8051–62.

32. Tanaka T, Minami M, Nakagawa T, Satoh M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res. 2004;48(4):463–9.

33. White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA. 2005;102(39):14092–7.

34. Jung H, Toth PT, White FA, Miller RJ. Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem. 2008;104(1):254–63.

35. Baba H, Ji RR, Kohno T, Moore KA, Ataka T, Wakai A, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci. 2003;24(3):818–30.

36. Zhang ZJ, Jiang BC, Gao YJ. Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. Cell Mol Life Sci. 2017;74(18):3275–91.

37. Chun S, Kwon YB. The CCL2 elevation in primary afferent fibers produces zymosan-induced hyperalgesia through microglia-mediated neuronal activation in the spinal dorsal horn. Brain Res Bull. 2019;149:53–9.

38. Wu R, Zhang PA, Liu X, Zhou Y, Xu M, Jiang X, et al. Decreased miR-325-5p contributes to visceral hypersensitivity through post-transcriptional upregulation of CCL2 in rat dorsal root ganglia. Neurosci Bull. 2019;35(5):791–801.

39. Li CL, Li KC, Wu D, Chen Y, Luo H, Zhao JR, et al. Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity. Cell Res. 2016;26(8):967.

40. Xie RG, Chu WG, Hu SJ, Luo C. Characterization of different types of excitability in large somatosensory neurons and its plastic changes in pathological pain states. Int J Mol Sci. 2018;19(1):161.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.